AIM
UBIO

Anchor Investment Management’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Anchor Investment Management’s Portfolio UBIO Stock Details UBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-275
Closed -$12.2K – 851
2018
Q3 		$12.2K Hold
275
– – ﹤0.01% 628
2018
Q2 		$9.12K Hold
275
– – ﹤0.01% 670
2018
Q1 		$8.75K Buy
+275
New +$10.1K ﹤0.01% 652

Other funds holding UBIO

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Anchor Investment Management's UBIO Position: Q4 2018 in Review

Anchor Investment Management sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q4 2018, closing a stake of 275 shares — an estimated $12.2K sold.

Anchor Investment Management first reported a position in UBIO in Q1 2018 and held it in 3 quarters. The position peaked at $12.2K in Q3 2018. 7 funds tracked by Wall St. Rank hold UBIO as of Q4 2018.

  • Anchor Investment Management reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Anchor Investment Management sold 275 Proshares UltraPro NASDAQ Biotechnology shares in Q4 2018, an estimated $12.2K.
  • Anchor Investment Management first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q1 2018 and held it in 3 quarters.
  • Anchor Investment Management's Proshares UltraPro NASDAQ Biotechnology position peaked at $12.2K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q4 2018.

Based on Anchor Investment Management's 13F filing for Q4 2018, filed 3 Jan 2024.